# US 8,277,780 B2 · Stable liquid desoximethasone compositions with reduced oxidized impurity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,780 B2
- Document ID: US8277780B2
- Status: Granted
- Kind: B2
- Application number: 11/921,106
- Filed: 2006-05-26
- Published: 2009-04-23
- Granted: 2012-10-02
- Earliest claimed: 2005-05-27
- Assignees: Taro Pharmaceutical North America, Inc.
- Inventors: Srinivasa Rao; Suresh Dixit; Avraham Yacobi; Arthur Bailey
- Web page: https://patentgrep.com/patent/US8277780B2

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C2-C4 alcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt % isopropyl myristate; c) about 20 wt % to about 70 wt % C2-C4 alcohol; and d) a stabilizing agent selected from the group consisting of an oleaginous vehicle and a propellant, wherein the stabilizing agent is in an amount sufficient to reduce the formation of less than about 1 wt % 17-carboxy-9α-fluoro-11β-hydroxy-16a-methyl-androsta-1,4-diene-3-one under an accelerated storage condition.

## Claims

### Claim 1

A liquid formulation comprising:
a) about 0.01 wt % to about 2.5 wt % desoximetasone;
b) about 10 wt % to about 70 wt % isopropyl myristate;
c) about 20 wt % to about 70 Wt % C2-C4 alcohol; and
d) a stabilizing agent comprising a mixture of
(a) an oleaginous vehicle selected from the group consisting of mineral oil and light mineral oil present in the amount of about 10 wt % to about 60 wt % and
(b) a skin conditioning agent selected from one or more of the group consisting of
(i) a C15-C25 fatty alcohol present in the amount of about 0.5 wt % to about 10 wt % and
(ii) an ester of glycerin and a C15-C25 fatty acid present in the amount of about 0.5 wt % to about 10 wt %.

### Claim 2 (depends on 1)

The liquid formulation of claim 1, wherein the desoximetasone is present in the amount of about 0.1 wt % to about 1 wt %.

### Claim 3 (depends on 1)

The liquid formulation of claim 1, wherein the desoximetasone is present in the amount of about 0.25 wt %.

### Claim 4 (depends on 1)

The liquid formulation of claim 1, wherein the isopropyl myristate is present in the amount of about 25 wt % to about 55 wt %.

### Claim 5 (depends on 1)

The liquid formulation of claim 1, wherein the isopropyl myristate is present in the amount of about 31.35 wt %.

### Claim 6 (depends on 1)

The liquid formulation of claim 1, wherein the C2-C4 alcohol is ethyl alcohol.

### Claim 7 (depends on 1)

The liquid formulation of claim 1, wherein the C2-C4 alcohol is isopropanol.

### Claim 8 (depends on 1)

The liquid formulation of claim 1, wherein the C2-C4 alcohol is present in the amount of about 20 wt % to about 40 wt %.

### Claim 9 (depends on 1)

The liquid formulation of claim 1, wherein the C2-C4 alcohol is present in the amount of about 23.4 wt %.

### Claim 10 (depends on 1)

The liquid formulation of claim 1, wherein the oleaginous vehicle is mineral oil.

### Claim 11 (depends on 1)

The liquid formulation of claim 1, wherein the oleaginous vehicle is present in the amount of about 20 wt % to about 50 wt %.

### Claim 12 (depends on 1)

The liquid formulation of claim 1, wherein the oleaginous vehicle is present in the amount of about 40 wt %.

### Claim 13 (depends on 1)

The liquid formulation of claim 1, wherein the skin conditioning agent comprises a ester of a glycerin and a C15-C25 fatty acid.

### Claim 14 (depends on 13)

The liquid formulation of claim 13, wherein the ester is a monoester.

### Claim 15 (depends on 13)

The liquid formulation of claim 13, wherein the C15-C25 fatty acid is oleic acid.

### Claim 16 (depends on 13)

The liquid formulation of claim 13, wherein the ester is glyceryl oleate.

### Claim 17 (depends on 13)

The liquid formulation of claim 13, wherein the ester is present in the amount of about 1 wt % to about 8 wt %.

### Claim 18 (depends on 13)

The liquid formulation of claim 13, wherein the ester is present in the amount of about 0.9 wt %.

### Claim 19 (depends on 1)

The liquid formulation of claim 1, wherein the skin conditioning agent comprises a C15-C25 fatty alcohol.

### Claim 20 (depends on 19)

The liquid formulation of claim 19, wherein the C15-C25 fatty alcohol is selected from the group consisting of lauryl alcohol, myristyl alcohol, palmityl alcohol, stearyl alcohol, linoleyl alcohol, and oleyl alcohol.

### Claim 21 (depends on 19)

The liquid formulation of claim 19, wherein the C15-C25 fatty alcohol is oleyl alcohol.

### Claim 22 (depends on 19)

The liquid formulation of claim 19, wherein the C15-C25 fatty alcohol is present in the amount of about 1 wt % to about 8 wt %.

### Claim 23 (depends on 19)

The liquid formulation of claim 19, wherein the C15-C25 fatty alcohol is present in the amount of about 5 wt %.

### Claim 24 (depends on 1)

The liquid formulation of claim 1, further comprising a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, butane, isobutane, propane, and dimethyl ether.

### Claim 25 (depends on 24)

The liquid formulation of claim 24, wherein the propellant is 1,1,1,2-tetrafluoroethane.

### Claim 26 (depends on 24)

The liquid formulation of claim 24, wherein the propellant is present in the amount of about 20 wt % to about 95 wt %.

### Claim 27 (depends on 24)

The liquid formulation of claim 24, wherein the propellant is present in the amount of about 40 wt % to about 80 wt %.

### Claim 28 (depends on 24)

The liquid formulation of claim 24, wherein the propellant is present in the amount of about 20 wt % to about 75 wt %.

### Claim 29 (depends on 1)

The liquid formulation of claim 1, further comprising a surfactant.

### Claim 30 (depends on 29)

The liquid formulation of claim 29, wherein the surfactant selected from the group consisting of sodium lauryl sulfate, and polysorbate 80.

### Claim 31 (depends on 29)

The liquid formulation of claim 29, wherein the surfactant is present in the amount of about 0.5 wt % to about 5 wt %.

### Claim 32 (depends on 1)

The liquid formulation of claim 1, further comprising water.

### Claim 33 (depends on 32)

The liquid formulation of claim 32, wherein the water is present in the amount of about 1 wt % to about 10 wt %.

### Claim 34 (depends on 1)

The liquid formulation of claim 1, wherein the liquid formulation comprises less than about 1 wt % 17-carboxy-9α-fluoro-11β-hydroxy-16α-methyl-androsta-1,4-diene-3-one after storage at 50° C., for 4 weeks.

### Claim 35 (depends on 1)

A dosage form comprising the liquid formulation of claim 1, and further comprising a pump delivery system.

### Claim 36 (depends on 1)

A dosage form comprising the liquid formulation of claim 1, and further comprising an aerosolized delivery system.

### Claim 37 (depends on 36)

The dosage form of claim 36, wherein the aerosolized delivery system comprises a can equipped with a continuous valve.

### Claim 38 (depends on 36)

The dosage form of claim 36, wherein the aerosolized delivery system comprises a can equipped with a metered-dosed valve.

### Claim 39 (depends on 1)

The liquid formulation of claim 1, wherein the liquid formulation is a foam.

### Claim 40 (depends on 39)

The liquid formulation of claim 39, wherein the foam is a quick-break foam.

### Claim 41 (depends on 1)

A method of treating a corticosteroid responsive dermatosis in a mammal comprising the step of topical administering to the mammal the aerosolized formulation of claim 1.

### Claim 42 (depends on 41)

The method of claim 41, wherein the corticosteroid responsive dermatosis is selected from the group consisting of plaque psoriasis, and atopic dermatitis.

### Claim 43 (depends on 1)

A process for preparing a liquid formulation of claim 1 comprising:
a) mixing desoximetasone in a C2-C4 alcohol to from a mixture;
b) adding isopropyl myristate in the mixture; and
c) adding stabilizing agent comprising a mixture of
(a) an oleaginous vehicle selected from the group consisting of mineral oil and light mineral oil present in the amount of about 10 wt % to about 60 wt % and
(b) a skin conditioning agent selected from one or more of the group consisting of
(i) a C15-C25 fatty alcohol present in the amount of about 0.5 wt % to about 10 wt % and
(ii) an ester of glycerin and a C15-C25 fatty acid present in the amount of about 0.5 wt % to about 10 wt %.

### Claim 44

A process for preparing an aerosolized formulation of desoximetasone comprising the step of filling an aerosol formulation into a container equipped with a continuous valve, said aerosol formulation comprising:
a) about 0.01 wt % to about 2.5 wt % desoximetasone;
b) about 10 wt % to about 70 wt % isopropyl myristate;
c) about 20 wt % to about 70 wt % C2-C4 alcohol; and
d) a stabilizing agent comprising a mixture of
(a) an oleaginous vehicle selected from the group consisting of mineral oil and light mineral oil present in the amount of about 10 wt % to about 60 wt % and
(b) a skin conditioning agent selected from one or more of the group consisting of
(i) a C15-C25 fatty alcohol present in the amount of about 0.5 wt % to about 10 wt % and
(ii) an ester of glycerin and a C15-C25 fatty acid present in the amount of about 0.5 wt % to about 10 wt %.

### Claim 45 (depends on 1)

The liquid formulation of claim 1, wherein the stabilizing agent is a mixture of mineral oil and glyceryl oleate.

### Claim 46 (depends on 1)

The liquid formulation of claim 1, wherein the stabilizing agent reduces the formation of 17-carboxy-9α-fluoro-11β-hydroxy-16α-methyl-androsta-1,4-diene-3-one after storage at 40° C., 75% relative humidity for 3 months to less than about 1 wt %.
